Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simethicone is an orally administered anti-foaming agent used to alleviate symptoms associated with excessive gastrointestinal gas, such as bloating, pressure, and flatulence. It functions as a surfactant by decreasing the surface tension of gas bubbles within the digestive tract, causing them to coalesce into larger bubbles that are more easily expelled via belching or flatus. Beyond its use as an over-the-counter treatment for dyspepsia and infantile colic, simethicone is widely utilized in clinical gastroenterology as an adjunct to bowel cleansing regimens (e.g., polyethylene glycol) prior to colonoscopy or capsule endoscopy. By eliminating foam and bubbles that can obscure the mucosal surface, it enhances visualization quality and may reduce the need for intraprocedural flushing, thereby potentially lowering the risk of endoscope-associated infections. Simethicone is chemically inert and not absorbed into the bloodstream, making it suitable for use in both pediatric and adult populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on simethicone.